Beijing, CARTITUDE-4, CARVYKTI, China, ciltacabtagene autoleucel, Clinical trials, Legend biotech, refractory multiple myeloma, Shanghai
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that ..
Beijing, Biotechnology, Cell therapy, Cellular therapy, China, Cilta-Cel, ciltacabtagene autoleucel, Legend biotech
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, ann..
CAR-T therapies, chimeric antigen receptors, China, ciltacabtagene autoleucel, Janssen Biotech, Legend biotech
CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma
March 2022: According to Johnson & Johnson, a therapy developed by the company and its China-based partner Legend Biotech Corp to treat a kind of white blood cell cancer has been approved by the US Food and Drug Administrati..
BCMA, CARVYKTI, ciltacabtagene autoleucel, immunomodulatory agent, Janssen Biotech, proteasome inhibitor
Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma
March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, the Food and Drug Administration has approved ciltacabtagene au..